ARROWHEAD PHARMACEUTICALS, INC. Additional Paid in Capital, Common Stock
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) had Additional Paid in Capital, Common Stock of $2.44 billion as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-04
- 2026-06-30: Additional Paid in Capital, Common Stock $2.44B.
- 2026-03-31: Additional Paid in Capital, Common Stock $2.40B.
- 2025-12-31: Additional Paid in Capital, Common Stock $2.21B.
- 2025-09-30: Additional Paid in Capital, Common Stock $2.14B.
| Period end | Additional Paid in Capital, Common Stock | Additional Paid in Capital, Common Stock as first filed |
|---|---|---|
| 2026-06-30 | $2.44B 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $2.40B 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $2.21B 10-Q · filed 2026-02-05 | |
| 2025-09-30 | $2.14B 10-Q · filed 2026-08-04 | |
| 2025-06-30 | $2.12B 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $2.11B 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $1.85B 10-Q · filed 2025-02-10 | |
| 2024-09-30 | $1.81B 10-K · filed 2025-11-25 | |
| 2024-06-30 | $1.79B 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $1.77B 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $1.32B 10-Q · filed 2024-02-06 | |
| 2023-09-30 | $1.30B 10-K · filed 2024-11-26 | |
| 2023-06-30 | $1.28B 10-Q · filed 2023-08-07 | |
| 2023-03-31 | $1.26B 10-Q · filed 2023-05-02 | |
| 2022-12-31 | $1.24B 10-Q · filed 2023-02-06 | |
| 2022-09-30 | $1.22B 10-K · filed 2023-11-29 | |
| 2022-06-30 | $1.19B 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $1.12B 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $1.08B 10-Q · filed 2022-02-02 | |
| 2021-09-30 | $1.05B 10-K · filed 2022-11-28 | |
| 2021-06-30 | $1.02B 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $996.64M 10-Q · filed 2021-05-04 | |
| 2020-12-31 | $978.65M 10-Q · filed 2021-02-04 | |
| 2020-09-30 | $965.41M 10-K · filed 2021-11-22 | $965.41M 10-K · filed 2020-11-23 |
| 2020-06-30 | $948.53M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $936.35M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $922.05M 10-Q · filed 2020-02-05 | |
| 2019-09-30 | $664.09M 10-K · filed 2020-11-23 | |
| 2019-06-30 | $657.14M 10-Q · filed 2019-08-05 | |
| 2019-03-31 | $652.41M 10-Q · filed 2019-05-08 | |
| 2018-09-30 | $582.90M 10-K · filed 2019-11-25 | |
| 2014-09-30 | $391.16M 10-K · filed 2014-11-25 | |
| 2014-06-30 | $388.56M 10-Q · filed 2014-08-12 | |
| 2014-03-31 | $381.97M 10-Q · filed 2014-05-06 | |
| 2013-12-31 | $259.37M 10-Q · filed 2014-02-04 | |
| 2013-09-30 | $193.51M 10-K · filed 2014-11-25 | |
| 2013-06-30 | $187.28M 10-Q · filed 2013-08-07 | |
| 2013-03-31 | $151.57M 10-Q · filed 2013-05-09 | |
| 2012-12-31 | $149.98M 10-Q · filed 2013-02-13 | |
| 2012-09-30 | $145.92M 10-K · filed 2013-12-18 | |
| 2012-06-30 | $139.94M 10-Q · filed 2012-08-13 | |
| 2012-03-31 | $136.49M 10-Q · filed 2012-05-08 | |
| 2011-12-31 | $136.32M 10-Q · filed 2012-02-09 | |
| 2011-09-30 | $127.48M 10-K · filed 2012-12-28 | |
| 2011-06-30 | $121.65M 10-Q · filed 2011-08-08 | |
| 2010-09-30 | $119.72M 10-K · filed 2011-12-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |